BeiGene and Zai Lab offer two ways to invest in what could be a big opportunity.
News & Analysis: BeiGene
One of America's largest biotechs will join hands with an industry leader in the rapidly expanding Chinese market.
A short-seller report weighed on the Chinese biotech's shares last month.
China's biopharma gem drifted lower in the first half of 2019, but there's no identifiable explanation or cause for concern.
Shares tumble in response to an industry megamerger.
A third-quarter report and a couple of priority reviews from the China Food and Drug Administration encouraged investors.
A slew of investor updates last month added about $2 billion to the company's market cap.
Celgene Corporation's partner in China is getting busy with tislelizumab.
The company's wallet is about to get a bit thicker.
The company inked a trans-formative deal with biotech behemoth Celgene last month.
The mid-cap Chinese biopharma announced a collaboration with Celgene that has a few interesting twists to it.